RxDoctor Payments Data

Alane Larison

Family · Mesa, AZNPI 1851799258

Payments from drug & device makers

$3,936in general payments, 2019–2025

Across 182 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$887
  • GSK$421
  • AbbVie$354
  • Biohaven Pharmaceuticals, Inc.$315
  • Boehringer Ingelheim$227
  • Pfizer$170
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$3,936100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,936 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$80,725
Medicare patients
201
Services billed
1,024

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin18$28,286
EliquisApixaban12$13,846
FarxigaDapagliflozin Propanediol12$12,684
BelsomraSuvorexant15$8,162
BenicarOlmesartan Medoxomil11$4,728
SynthroidLevothyroxine Sodium57$4,214
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$3,080
Levothyroxine Sodium271$2,115
HumalogInsulin Lispro11$1,312
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst62$1,234
Losartan Potassium137$1,108
Potassium Chloride39$1,069
Gabapentin49$992
Pantoprazole Sodium64$985
Lisinopril170$970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$227$28,28618 claims
PfizerEliquis$170$13,84612 claims
AstraZenecaFarxiga$887$12,68412 claims
MerckBelsomra$60$8,16215 claims
AbbVieSynthroid$354$4,21457 claims
Lilly USA, LLCHumalog$79$1,31211 claims
Almatica Pharma LLCSertraline Hcl$24$44462 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.

Other family in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →